Queen Mary Utilization of Antihypertensive Drugs Study: Side-effects of antihypertensive drugs

Journal of Clinical Pharmacy and Therapeutics

Volumn 30, Issue 4, 2005, Pages 391-399

  Cheung, B M Y ^a,d   Wong, Y L ^b,c   Lau, C P ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF SUNDERLAND   (United Kingdom)

^d QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

blocker; Angiotensin converting enzyme inhibitor; Calcium channel blocker; Drug utilization; Hypertension; Thiazide diuretic

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METHYLDOPA; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

ADULT; AGED; ANKLE EDEMA; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; COUGHING; DIZZINESS; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; FLUSHING; GASTROINTESTINAL DISEASE; HEADACHE; HEALTH SURVEY; HEART RATE; HUMAN; HYPERTENSION; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; POLYURIA; RASH; SEDATION; SEX DIFFERENCE; SIDE EFFECT; TACHYCARDIA; THORAX DISEASE; TREATMENT OUTCOME; XEROSTOMIA; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; DRUG EFFECT; EPIDEMIOLOGY; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HEALTH CARE SURVEYS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PATIENT COMPLIANCE;

EID: 26944480136     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2005.00662.x     Document Type: Article

References (36)

1. Staessen JA, Wang JG, Thijs L (2001) Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet, 358, 1305-1315.
2. Hajjar I, Kotchen TA (2003) Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA, 290, 199-206.
3. Cheung BMY, Law FCY, Lau CP (2002) The rule of halves applies in Chinese hypertensive patients. American Journal of Hypertension, 15, 209A.
4. Cheung BMY, Cheung AHK, Ho SPC, Lau CP, Kumana CR (1999) Utilisation of antihypertensive drugs in a hypertension clinic in 1996 & 1998. Journal of Clinical Pharmacology, 39, 969A.
5. Wong YL, Cheung BMY (2004) Utilisation of anti-hypertensive drugs in a hypertension outpatient clinic in 1998 & 2004. Cardiovascular Drugs and Therapy, 18 (Suppl. 1), 23A.
6. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 317, 703-713.
7. Lazarus JM, Bourgoignie JJ, Buckalew VM et al. (1997) Achievement and safety of a low blood pressure goal in chronic renal disease: the Modificaton of Diet in Renal Disease Study Group. Hypertension, 29, 641-650.
8. Chobanian AV, Bakris GL, Black HR et al (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA, 289, 2560-2572.
9. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 288, 2981-2997.
10. Hansson L, Lindholm LH, Ekbom T et al. (1999) Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet, 354, 1751-1756.
11. Wing LM, Reid CM, Ryan P et al. (2003) A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. New England Journal of Medicine, 348, 583-592.
12. The Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New England Journal of Medicine, 342, 145-153.
13. PROGRESS Collaborative Group (2001) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet, 358, 1033-1041.
14. Woo KS, Morris RM, Nicholls G (1995) Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities). American Journal of Cardiology, 75, 967-968.
15. MRC Working Party (1992) Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ, 304, 405-412.
16. Dahlof B, Devereux RB, Kjeldsen SE et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 359, 995-1003.
17. Messerli FH, Beevers DG, Franklin SS, Pickering TG (2003) β-blockers in hypertension - the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension. American Journal of Hypertension, 16, 870-873.
18. Carlberg B, Samuelsson O, Lindholm LH (2004) Atenolol in hypertension: is it a wise choice? Lancet, 364, 1684-1689.
19. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini C, Furberg CD (2000) Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet, 356, 1949-1954.
20. Staessen JA, Fagard R, Thijs L et al. (1997) Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet, 350, 757-764.
21. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM (2000) Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet, 356, 366-372.
22. Blood Pressure Lowering Treatment Trialists' Collaboration (2000) Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet, 355, 1955-1964.
23. Lau CP, Cheung BMY (1996) Relative efficacy and tolerability of lacidipine and amlodipine in patients with mild-to-moderate hypertension: a randomised double-blind study. Journal of Cardiovascular Pharmacology, 28, 328-331.
24. Cheung BMY, Lau CP, Wu BZ (1998) Efficacy and tolerability of three new dihydropyridine calcium channel blockers: amlodipine, felodipine and isradipine. Clinical Therapeutics, 20, 1159-1169.
25. Chou CC, Lee MS, Ke CH, Chung MH (2004) Prescription patterns of hypertension - National Health Insurance in Taiwan. Journal of Chinese Medical Association, 67, 123-130.
26. Cheung BMY, Law FCY, Tam SCF, Kumana CR, Lau CP (2002) Plasma renin activity and aldosterone level in patients with essential hypertension. American Journal of Hypertension, 15, 210A.
27. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ (1999) Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet, 353, 2008-2013.
28. Williams B, Poulter NR, Brown MJ et al. (2004) Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 - BHS IV. Journal of Human Hypertension, 18, 139-185.
29. Julius S, Kjelsen SE, Weber M et al. (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 363, 2022-2031.
30. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. New England Journal of Medicine, 329, 1456-1462.
31. Brenner BM, Cooper ME, de Zeeuw D et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine, 345, 861-869.
32. Lewis EJ, Hunsicker LG, Clarke WR et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine, 345, 851-860.
33. Whitworth JA, World Health Organization, International Society of Hypertension Writing Group (2003) World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. Journal of Hypertension, 21, 1983-1992.
34. European Society of Hypertension-European Society of Cardiology Guidelines Committee (2003) European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. Journal of Hypertension, 21, 1011-1053.
35. Cheung BMY, Lau CP, Kumana CR (2003) Combination therapy for hypertension. Hong Kong Medical Journal, 9, 224-226.
36. Hansson L, Zanchetti A, Carruthers SG et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet, 51, 1755-1762.